Pseudomonas Infections

Mechanisms of Resistance
Molecular Characterization of Carbapenemase-Producing Pseudomonas aeruginosa of Czech Origin and Evidence for Clonal Spread of Extensively Resistant Sequence Type 357 Expressing IMP-7 Metallo-β-Lactamase
Costas C. Papagiannitsis, Matej Medvecky, Katerina Chudejova, Anna Skalova, Veronika Rotova, Petra Spanelova, Vladislav Jakubu, Helena Zemlickova, Jaroslav Hrabak
and on behalf of Czech Participants of the European Antimicrobial Resistance Surveillance Network
Mechanisms of Resistance
Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation
Shawn H. MacVane, Ruchi Pandey, Lisa L. Steed, Barry N. Kreiswirth, Liang Chen
Experimental Therapeutics
An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections
Martina Koeva, Alina D. Gutu, Wesley Hebert, Jeffrey D. Wager, Lael M. Yonker, George A. O'Toole, Frederick M. Ausubel, Samuel M. Moskowitz, Diane Joseph-McCarthy
Pharmacology
Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes
Rajbharan Yadav, Jürgen B. Bulitta, Jiping Wang, Roger L. Nation, Cornelia B. Landersdorfer
Pharmacology
Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling
Rajbharan Yadav, Jürgen B. Bulitta, Elena K. Schneider, Beom Soo Shin, Tony Velkov, Roger L. Nation, Cornelia B. Landersdorfer
Experimental Therapeutics
Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection
Bryan J. Berube, Katherine R. Murphy, Matthew C. Torhan, Nicholas O. Bowlin, John D. Williams, Terry L. Bowlin, Donald T. Moir, Alan R. Hauser
Clinical Therapeutics
Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis
Timothy J. Bensman, Joshua Wang, Jordanna Jayne, Lynn Fukushima, Adupa P. Rao, David Z. D'Argenio, Paul M. Beringer
Susceptibility
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds
Mordechai Grupper, Christina Sutherland, David P. Nicolau
Clinical Therapeutics
The Nonantibiotic Macrolide EM703 Improves Survival in a Model of Quinolone-Treated Pseudomonas aeruginosa Airway Infection
Gopinath Kasetty, Ravi K. V. Bhongir, Praveen Papareddy, Heiko Herwald, Arne Egesten
Open Access

Pharmacology
Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics
Shuhei Matsumoto, Christine M. Singley, Jennifer Hoover, Rio Nakamura, Roger Echols, Stephen Rittenhouse, Masakatsu Tsuji, Yoshinori Yamano

Pages